Development of a Family-Based Treatment for Adolescent Methamphetamine Use - Full Text View

Sponsors and Collaborators:	Oregon Research Institute National Institute on Drug Abuse (NIDA)
Information provided by:	Oregon Research Institute
ClinicalTrials.gov Identifier:	NCT00680511

Purpose

The AIMS study compares a methamphetamine-specific treatment intervention to a treatment-as-usual Functional Family Therapy (FFT) approach for adolescents ages 15 to 19. Adolescents are assigned to one of two treatment conditions: (1) 16 weeks of FFT designed to strengthen family relationships and develop skills for helping the adolescent avoid drug use; or (2) 16 weeks of a combination of FFT and a methamphetamine-specific intervention involving group and individual therapy sessions; Families are assessed using questionnaires and interviews, and adolescents participate in neuropsychological testing, before, during, and after treatment to provide information about family functioning, the adolescent's drug use, the adolescent's peers, and other factors that may contribute to treatment success. Adolescents also provide urine specimens for drug screening at assessment visits. Through a partnership with Oregon Health and Science University (OHSU), adolescents will participate in functional magnetic resonance imaging appointments at the hospital to examine regional brain blood flow during tasks designed to measure impulsivity and risk-taking behaviors. As a treatment development grant, study investigators will study adolescents' acceptance of and response to the newly developed methamphetamine-specific treatment approach.

Condition	Intervention	Phase
Behavior and Mental Disorders Methamphetamine Disorders	Behavioral: Adolescent Methamphetamine Treament (AMT) Behavioral: Functional Family Therapy (FFT)	Phase I

MedlinePlus related topics: Child Mental Health Mental Health Methamphetamine

Drug Information available for: Amphetamine Methamphetamine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment
Official Title:	Development of a Family-Based Treatment for Adolescent Methamphetamine Use

Further study details as provided by Oregon Research Institute:

Primary Outcome Measures:

Substance Use [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Engagement and retention of adolescent methamphetamine users. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment:	60
Study Start Date:	September 2007
Estimated Study Completion Date:	May 2011
Estimated Primary Completion Date:	May 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Active Comparator Family therapy combined with methamphetamine-specific group treatment.	Behavioral: Adolescent Methamphetamine Treament (AMT) AMT Group Therapy plus Functional Family Therapy (FFT)
2: Active Comparator Family Therapy.	Behavioral: Functional Family Therapy (FFT) FFT

Eligibility

Ages Eligible for Study:	15 Years to 19 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

15 to 19 years of age.
Have at least one parent or parent figure willing to participate.
Meet DSM-IV diagnostic criteria for drug-abuse or dependence, including a specific meth use disorder.
Reports meth use on at least 5 of the previous 90 days.
Have contact with the parent on at least 40% of the past 90 days.
With their parent be willing to accept randomization to one of the two treatment interventions.
Be willing to participate in the imaging task in the fMRI pilot study.
Have basic English competency.
Have sufficient residential stability to permit probable contact at follow-up.

Exclusion Criteria:

Evidence of psychotic or organic state of sufficient severity to interfere with understanding of study instruments and procedures.
Have a medical or psychological condition that would preclude undergoing the fMRI scan.
Have a sibling who is participating in the study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00680511

Contacts

Contact: Erica Finstad, Ph.D.

503-243-1065

efinstad@ori.org

Locations

United States, Oregon
Oregon Research Institute Center for Family and Adolescent Research	Recruiting
Portland, Oregon, United States, 97205
Contact: Erica Finstad, Ph.D. 503-243-1065 efinstad@ori.org

Sponsors and Collaborators

Oregon Research Institute

National Institute on Drug Abuse (NIDA)

Investigators

Principal Investigator:

Holly B. Waldron, Ph.D.

Oregon Research Institute

More Information

Related Info This link exits the ClinicalTrials.gov site

Responsible Party:	Oregon Research Institute ( Holly Barrett Waldron, Ph.D. )
Study ID Numbers:	DA021695
Study First Received:	May 16, 2008
Last Updated:	November 3, 2008
ClinicalTrials.gov Identifier:	NCT00680511
Health Authority:	United States: Institutional Review Board

Keywords provided by Oregon Research Institute:

methamphetamine abuse

Study placed in the following topic categories:

Methamphetamine
Dopamine
Mental Disorders
Amphetamine

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Disease
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Uptake Inhibitors
Sympathomimetics
Physiological Effects of Drugs

Central Nervous System Stimulants
Pharmacologic Actions
Pathologic Processes
Autonomic Agents
Therapeutic Uses
Dopamine Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 14, 2009